{"id":"NCT01929044","sponsor":"Boehringer Ingelheim","briefTitle":"Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain","officialTitle":"A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2013-08-27","resultsPosted":"2016-03-08","lastUpdate":"2016-03-08"},"enrollment":299,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Intestinal Diseases"],"interventions":[{"type":"DRUG","name":"654-II (anisodamine)","otherNames":[]},{"type":"DRUG","name":"Buscopan® (hyoscine butylbromide)","otherNames":[]}],"arms":[{"label":"Buscopan® (hyoscine butylbromide)","type":"EXPERIMENTAL"},{"label":"654-II(anisodamine)","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study is to assess the efficacy of Buscopan® (hyoscine butylbromide) in comparison to 654-II (anisodamine)in acute gastric or intestinal spasm-like pain.","primaryOutcome":{"measure":"PID From Pre-dose Baseline at 20 Minutes After First Injection.","timeFrame":"Baseline and 20 minutes after the first injection","effectByArm":[{"arm":"Buscopan® (Hyoscine Butylbromide)","deltaMin":-4.09,"sd":0.17},{"arm":"654-II (Anisodamine)","deltaMin":-3.66,"sd":0.18}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0743"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":20,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":153},"commonTop":["Thirst"]}}